Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist.[1] Gilead Colorado, a subsidiary of Gilead Sciences,[2] under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Elimination half-life | 12.5 hours |
Identifiers | |
| |
CAS Number | |
ECHA InfoCard | 100.126.841 |
Chemical and physical data | |
Formula | C22H22N2O6 |
Molar mass | 410.426 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field.[3]
In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study, but was terminated because the study did not reach its primary endpoints.[4]
See also
editReferences
edit- ^ Enseleit F, Lüscher TF, Ruschitzka F (August 2010). "Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension" (PDF). Therapeutic Advances in Cardiovascular Disease. 4 (4): 231–40. doi:10.1177/1753944710373785. PMID 20660536. S2CID 22533124.
- ^ Gilead Sciences[permanent dead link]
- ^ "Darusentan - Gilead Sciences". Adis Insight. Springer Nature Switzerland AG.
- ^ Clinical trial number NCT00389675 for "DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension (Darusentan)" at ClinicalTrials.gov
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.